BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 11, 2019
Targets & Mechanisms

CAR Ts can move well beyond cancer, but will need to go allogeneic first

CAR Ts could move into autoimmunity, infections and more, if researchers can solve the allogeneic question.
BioCentury | Jan 24, 2019
Emerging Company Profile

Cabaletta’s CAAR Ts for autoimmunity

How Cabaletta is treating B cell-mediated autoimmunity without wiping out all B cells
BioCentury | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Desmoglein 3 (DSG3)

BioCentury | Jul 21, 2016
Tools & Techniques

A new route for CARs

Adapting CAR T technology to treat autoimmune diseases
BioCentury | Nov 13, 2006
Company News

Peptimmune, Orphan Europe deal

Items per page:
1 - 10 of 12